Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9 |
High Similarity |
NPD3027 |
Phase 3 |
0.8561 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8519 |
High Similarity |
NPD3620 |
Phase 2 |
0.8519 |
High Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.8496 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8382 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8382 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8333 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8254 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8243 |
Intermediate Similarity |
NPD37 |
Approved |
0.8235 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8222 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8162 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.812 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.812 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8095 |
Intermediate Similarity |
NPD228 |
Approved |
0.8079 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8079 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8079 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8045 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8015 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7985 |
Intermediate Similarity |
NPD4749 |
Approved |
0.797 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7962 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7941 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7937 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7937 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7852 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7842 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7821 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.78 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7793 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7785 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.773 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7704 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7676 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7669 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7647 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7643 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7622 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7597 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7554 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7552 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7551 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7547 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7519 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7517 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7483 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7482 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7469 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7466 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7466 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7465 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7465 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7465 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.745 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7448 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7445 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7439 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7415 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7391 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7389 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7372 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7368 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7351 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7351 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7351 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7338 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7333 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.732 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7305 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7302 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7299 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7297 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7286 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7279 |
Intermediate Similarity |
NPD3091 |
Approved |
0.7273 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7273 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7267 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7255 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7248 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7233 |
Intermediate Similarity |
NPD4055 |
Discovery |
0.7226 |
Intermediate Similarity |
NPD7261 |
Clinical (unspecified phase) |
0.7226 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7222 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7219 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7219 |
Intermediate Similarity |
NPD5241 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD3060 |
Approved |
0.719 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7185 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7183 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7181 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7179 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7179 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7176 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7172 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7163 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7163 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.716 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7152 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD4579 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD5090 |
Approved |
0.7134 |
Intermediate Similarity |
NPD5089 |
Approved |
0.7133 |
Intermediate Similarity |
NPD7037 |
Approved |
0.7125 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD7833 |
Phase 2 |
0.7125 |
Intermediate Similarity |
NPD7832 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD7831 |
Phase 2 |
0.7124 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7123 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7121 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7109 |
Intermediate Similarity |
NPD940 |
Approved |
0.7109 |
Intermediate Similarity |
NPD846 |
Approved |
0.7108 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7107 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7103 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7103 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7103 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7102 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7099 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7095 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7095 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7092 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7091 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.709 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7086 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7078 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7078 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7073 |
Intermediate Similarity |
NPD27 |
Approved |
0.7073 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7071 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7071 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.707 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7055 |
Intermediate Similarity |
NPD3051 |
Approved |
0.705 |
Intermediate Similarity |
NPD3019 |
Approved |
0.705 |
Intermediate Similarity |
NPD4059 |
Approved |
0.705 |
Intermediate Similarity |
NPD5846 |
Approved |
0.705 |
Intermediate Similarity |
NPD3095 |
Discontinued |
0.705 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7048 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7047 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7047 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7044 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7041 |
Intermediate Similarity |
NPD4578 |
Approved |
0.7041 |
Intermediate Similarity |
NPD4577 |
Approved |
0.7039 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7037 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7027 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7021 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7021 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7021 |
Intermediate Similarity |
NPD2230 |
Approved |
0.702 |
Intermediate Similarity |
NPD4664 |
Clinical (unspecified phase) |
0.7018 |
Intermediate Similarity |
NPD4663 |
Approved |
0.7013 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7013 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7012 |
Intermediate Similarity |
NPD2970 |
Approved |
0.7012 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7007 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7006 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7006 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD6190 |
Approved |
0.6986 |
Remote Similarity |
NPD6812 |
Clinical (unspecified phase) |
0.6984 |
Remote Similarity |
NPD2859 |
Approved |
0.6984 |
Remote Similarity |
NPD2860 |
Approved |
0.6982 |
Remote Similarity |
NPD7549 |
Discontinued |
0.698 |
Remote Similarity |
NPD6896 |
Approved |
0.698 |
Remote Similarity |
NPD6895 |
Approved |
0.6978 |
Remote Similarity |
NPD4093 |
Discontinued |
0.6978 |
Remote Similarity |
NPD5691 |
Approved |
0.6977 |
Remote Similarity |
NPD7906 |
Approved |
0.6974 |
Remote Similarity |
NPD4237 |
Approved |
0.6974 |
Remote Similarity |
NPD4236 |
Phase 3 |
0.6972 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6972
|
Remote Similarity |
NPD6583 |
Phase 3 |